# Pathophysiology of diabetes mellitus

prof. MUDr. Mária Pallayová, PhD.

maria.pallayova@upjs.sk

UPJŠ LF Košice, 17. apríl 2026

## Definition

- Diabetes mellitus is a heterogeneous group of metabolic disorders whose common denominator is **chronic hyperglycemia**. It arises either from **insufficient insulin secretion**, **impaired insulin action**, or a combination of both mechanisms.
- Long-term hyperglycemia subsequently damages blood vessels, nerves, kidneys, eyes, and other organ systems; from the perspective of a dentist, it is particularly important that it worsens periodontal health, wound healing, and resistance to infections in the oral cavity.

# Why diabetes is crucial for modern medicine

*Epidemic, multi-organ consequences, economic impact*

- According to the IDF, approximately **589 million adults** were living with diabetes in 2024, meaning about **1 in 9 adults worldwide**.
- More than **40% of cases remain undiagnosed**, so complications often develop even before the diagnosis is established.
- The pathophysiology of complications does not begin only after the “official diagnosis”; for many years, diabetes is a silent systemic disease and a core condition across internal medicine, nephrology, ophthalmology, neurology, surgery, and obstetrics.
- More than **90%** of cases are **T2DM**, but **T1DM**, gestational diabetes, and secondary forms have high individual morbidity.
- Diabetes substantially increases the risk of **CKD, retinopathy, neuropathy, atherosclerosis, heart failure, and infections**.
- From the perspective of the healthcare system, it is a paradigmatic example of a disease in which **prevention and early intervention are less costly than treating complications**.

**Current global figures**

**589 million adults with diabetes**

**252 million undiagnosed**

**853 million projected by 2050**

**≥ 90% of cases are T2DM**

Statistics are based on the IDF Diabetes Atlas, 11th edition (2025).

# HISTORY OF  DIABETES MELLITUS

**Prehistoric period**

- It is not known when diabetes as a disease first affected humans.
- In southern Moravia and the adjacent area of southwestern Slovakia more than 20,000 years ago, during the Paleolithic???
- The realistic figurine of the Venus of Věstonice – overall obesity, rarity, a symbol of prosperity and fertility (a symbol of a fertility cult from the Stone Age).

**Ancient Times – the first observations (≈ 1500 BC) and the Middle Ages**

- **Ancient Egypt** – in the Ebers Papyrus (≈ 1550 BC)
  - a disease characterized by excessive urination is described, the first description of diabetes as an illness in which the patient suffers from intense thirst and urinates constantly, while the "body wastes away and is excreted in the urine"
- **India (Ayurveda, Sanskrit literature)**
  - the term **"madhumeha"** = **"honey urine"**
  - physicians noticed that urine attracts ants
  - the disease was **clinically recognized**, but without understanding its mechanism, with a distinction between **two forms of diabetes**


Urine was droped on the ground
If urine contains sugar, then ants will be attracted to it
Urine
Urine
Ant
labpedia.net

**Antiquity – naming of the disease**

**1st–2nd century AD**

- **Aretaeus of Cappadocia**
  - first used the term **“diabetes”** (“passing through” / “siphon”) based on the Greek word **diabainein** (to pass through something)
  - description: **“the body dissolves into urine”**
  - in this period, the disease was **rare and fatal**, and treatment was practically nonexistent
- **Galen** – diet, physical exercise, hydrotherapy

**9th century AD** – **Avicenna** – complications – **diabetic foot**

**Aretaeus of Cappadocia, 150 AD**

"Diabetes is a remarkable disorder, and not one very common to man. It consists of a moist and cold wasting of the flesh and limbs into urine... the secretion passes in the usual way, by the kidneys and the bladder. It is of improbable, also, that something pernicious, derived from other disease which attack the bladder and kidneys may sometimes prove the cause of this affliction. The patients never cease making water, but the discharge is as incessant as a sluice let off. This disease is chronic in character, and is slowly engendered, though the patient does not survive long when it is completely established for the marasmus produced is rapid and death is speedy."

## Modern Era

- **Scientific research on diabetes**
- **1674 – Thomas Willis** – distinguished diabetes from other polyuric conditions; he tasted urine and found it to be sweet; he added the term **“mellitus”** (honeyed, sweet), distinguishing **diabetes mellitus** from **diabetes insipidus**; diagnosis was still based only on symptoms.
- **1869 – Paul Langerhans** – described the **islets of the pancreas**.
- **1889 – Oskar Minkowski and Joseph von Mering** → removal of the pancreas in a dog → development of diabetes, the first proof that the pancreas is connected with diabetes.
- **1909 – Jean de Meyer** – proposed a hypothetical hormone that lowers blood sugar levels and introduced the name **insulin**.





# UNTERSUCHUNGEN

ÜBER DEN

# DIABETES MELLITUS

NACH

# EXSTIRPATION DES PANKREAS.

VON

**O. MINKOWSKI,**

A. O. PROFESSOR AN DER UNIVERSITÄT ZU STRASSBURG.

---

Aus dem Laboratorium der medicinischen Klinik zu Strassburg i. E.

SONDERABDRUCK.

## 20th century – the revolution: insulin

- **Frederick Banting and Charles Best (1921)**
  - isolation of **insulin** from the pancreas of a dog; the hormone, originally called **isletin**, effectively reduced hyperglycemia in dogs with experimental diabetes
- **first patient:**
  - **Leonard Thompson**
- **1923 – Nobel Prize for the discovery of insulin**
- **diabetes changed from a fatal disease into a treatable one**

Insulin does not belong to me,
it belongs to the world.
~ Frederick Banting






**Second half of the 20th century – understanding of pathophysiology**

- **distinction:**
  - **Type 1 DM** – autoimmune destruction of β-cells
  - **Type 2 DM** – insulin resistance
- **discoveries:**
  - insulin receptor
  - signaling mechanisms

*1955 – F. Sanger – precisely described the structure of the insulin molecule (Nobel Prize, 1958)*

*1966 – G. Katsoyannis – chemical synthesis of insulin*

- **development of:**
  - glucose meters
  - oral antidiabetic drugs

# Historical Discoveries and Milestone Events in Pancreatic Research



## 21st century – the modern era

- **technology:**
  - **CGM** (continuous glucose monitoring)
  - insulin pumps
  - “artificial pancreas”
- **treatment:**
  - GLP-1 agonists
  - SGLT2 inhibitors
- **research:**
  - gene therapy
  - islet transplantation




***How does a closed-loop artificial pancreas system work?***




# Physiological basis

*– normal glucose homeostasis*

insulin and glucagon as the regulatory axis

temporal difference between fasting and the postprandial state

organ communication: pancreas – liver – muscle – adipose tissue – gut – kidney – CNS

- most subsequent “pathological” processes are in fact an extreme or a failure of normal physiological regulatory mechanisms

# Normal glucose homeostasis

*Dynamic balance between glucose intake, production, and utilization*




- **In the postprandial state**, insulin secretion increases, glucagon decreases, the liver switches from glucose production to glucose storage, and muscle and adipose tissue increase glucose uptake via GLUT4.
- **During fasting**, it is physiological for the liver to produce glucose.
- Diabetes does not arise only from **"insulin deficiency,"** but also from the inability to suppress hepatic glucose production or from the inability of peripheral tissues to utilize glucose.
- **The role of the kidney** – in hyperglycemia, it ceases to be only a passive filter and becomes an active player through the glucose threshold and SGLT2.
- **Glycemia is the result of the sum of organ fluxes, not an isolated function of the pancreas.**

# Pancreatic β-cell: glucose sensor and timer of anabolism

*What must function properly for insulin secretion to be normal*

- Glucose enters the β-cell, increases the ATP/ADP ratio, closes KATP channels, depolarizes the membrane, and opens Ca2+ channels.
- Ca2+-dependent exocytosis releases insulin in a biphasic profile: a rapid first phase and a slower second phase.
- Insulin secretion is modulated by incretins, the autonomic nervous system, amino acids, and fatty acids.
- A functional β-cell does not only mean the ability to produce insulin, but also the ability to respond appropriately to the pace and amplitude of the metabolic stimulus.
- In T2DM, an early loss of the first phase of secretion is often present even before fully developed chronic hyperglycemia (postprandial hyperglycemia tends to appear earlier than persistent fasting hyperglycemia).

**Key points of the β-cell**

- glucose sensor
- KATP–Ca2+ exocytosis
- first vs. second phase of secretion
- incretin amplification

*Loss of the first phase of secretion is an early sign of β-cell dysfunction in T2DM.*

# Pancreatic β-cell: glucose sensor and timer of anabolism

*What must function properly for insulin secretion to be normal*

- **KATP–$Ca^{2+}$ exocytosis = the basic mechanism of insulin secretion from pancreatic β-cells:**
- **Blood glucose rises** → glucose enters the β-cell.
- **ATP production increases.**
- ATP **closes KATP channels** (ATP-sensitive potassium channels).
- This reduces **$K^+$ efflux** from the cell and causes **membrane depolarization**.
- Depolarization opens **voltage-gated $Ca^{2+}$ channels**.
- **$Ca^{2+}$ enters the cell.**
- The rise in intracellular **$Ca^{2+}$** triggers **exocytosis of insulin granules**.

***Increase in ATP → closure of KATP channels → membrane depolarization → opening of $Ca^{2+}$channels → $Ca^{2+}$influx → insulin exocytosis***

**Key points of the β-cell**

- glucose sensor
- KATP–Ca2+ exocytosis
- first vs. second phase of secretion
- incretin amplification

*Loss of the first phase of secretion is an early sign of β-cell dysfunction in T2DM.*

# Insulin signaling in target tissues

*Where insulin resistance arises*

- Binding of insulin to its receptor activates tyrosine kinase signaling and the IRS–PI3K–Akt and MAPK pathways.
- **IRS–PI3K–Akt and MAPK** denote the two main intracellular signaling branches that are activated after **insulin binds to the insulin receptor**.
- **IRS–PI3K–Akt** mediates the metabolic effects of insulin.
- **MAPK** mediates growth-promoting, proliferative, and gene-regulatory effects.

*Tissue-specific insulin resistance helps explain the phenotypic heterogeneity of T2DM.*

**Schematic illustration of the insulin signaling pathway.** Insulin binds to the insulin receptor, which leads to activation of IRS-1 and PI3K. PI3K catalyzes the conversion of PIP2 to PIP3, which activates PDK1. PDK1, together with mTORC2, phosphorylates and activates Akt. Activated Akt promotes the translocation of GLUT4 to the plasma membrane, thereby increasing glucose uptake, and inhibits GSK-3, which stimulates glycogen synthase activity and glycogen synthesis.

**IRS-1**, insulin receptor substrate 1;
**PI3K**, phosphatidylinositol 3-kinase;
**PIP2**, phosphatidylinositol 4,5-bisphosphate;
**PIP3**, phosphatidylinositol 3,4,5-trisphosphate;
**PDK1**, phosphoinositide-dependent kinase 1;
**mTORC2**, mechanistic target of rapamycin complex 2;
**Akt**, protein kinase B;
**GLUT4**, glucose transporter 4;
**GSK-3**, glycogen synthase kinase-3.



# Insulin signaling in target tissues

*Where insulin resistance arises*

## Significance in the pathophysiology of DM:

- In **insulin resistance**, the **IRS–PI3K–Akt branch** is usually more impaired, that is, the **metabolic effect of insulin**, whereas the **MAPK branch** may remain relatively preserved. This is important because:
- glucose utilization decreases,
- hepatic glucose production increases,
- endothelial dysfunction persists,
- at the same time, some proliferative and proatherogenic effects of insulin may remain preserved.

*Tissue-specific insulin resistance helps explain the phenotypic heterogeneity of T2DM.*

# Insulin signaling in target tissues

*Where insulin resistance arises*

- Binding of insulin to its receptor activates tyrosine kinase signaling and the IRS–PI3K–Akt and MAPK pathways.
- Metabolic effects – GLUT4 translocation, inhibition of lipolysis, and suppression of hepatic gluconeogenesis – depend mainly on the PI3K–Akt axis.
- Chronic excess energy supply, inflammation, ectopic lipids, and serine phosphorylation of IRS disrupt the signal even before glucose transport itself.
- Insulin resistance is not a binary phenomenon; it may be selective and tissue-specific.
- Clinically, this explains why a patient may simultaneously have hyperglycemia, hyperinsulinemia, hepatic steatosis, and persistent lipogenesis.
- A defect in the signaling pathway leads to reduced glucose uptake in muscle, persistent glucose production in the liver, and insufficient suppression of lipolysis in adipose tissue.
- **“Selective” insulin resistance** = the liver is resistant to the suppression of gluconeogenesis, while at the same time remaining relatively sensitive to lipogenic signals.

**Sites of signal failure**

- receptor / IRS
- PI3K–Akt pathway
- GLUT4 translocation
- selective hepatic resistance

*Tissue-specific insulin resistance helps explain the phenotypic heterogeneity of T2DM.*

# Organ network in glycemic regulation

*Diabetes is a disorder of inter-organ communication*




The **multi-organ concept of T2DM** means that in diabetes we always ask which organ dominates the patient’s phenotype. The **liver** determines fasting glycemia, **muscle** is crucial after meals, **adipose tissue** supplies the body with free fatty acids and inflammatory mediators, the **gut** modifies the response through incretins, the **kidney** modulates glucose reabsorption, and the **CNS** influences both food intake and energy expenditure. Within this framework, diabetes appears as a failure of coordination, not as an isolated disorder of a single hormone.

# Classification and Diagnosis

*Hyperglycemia is a syndrome; a diagnosis of “diabetes” does not yet determine the underlying mechanism.*

- four basic diagnostic categories
- criteria for diagnosis and prediabetes
- clinical warning signs of misclassification

*The same laboratory criteria may lead to very different pathophysiological diagnoses. That is why it is important to consider age, BMI, speed of symptom onset, autoimmunity, family history, medications, pregnancy, and pancreatic diseases.*

## Classification

## Note

- terminology is not yet fully standardized across all sources
- in its 2026 Standards, the ADA still relies on conventional clinical categories of diabetes
- in 2025, the IDF officially recognized **malnutrition-related diabetes mellitus** as **type 5 diabetes**, and is still in the process of developing formal diagnostic criteria and therapeutic recommendations for this entity

**Current Classification of Diabetes Mellitus**

- **Type 1 diabetes mellitus** – autoimmune diabetes characterized by destruction of pancreatic β-cells and an absolute or near-absolute insulin deficiency.
- **Type 2 diabetes mellitus** – diabetes based on a combination of insulin resistance and progressive β-cell failure; it is the most common type of diabetes and, according to the WHO, accounts for more than 95% of all diabetes cases worldwide.
- **Hyperglycemia first detected in pregnancy** – this includes both **gestational diabetes mellitus** and **diabetes in pregnancy** meeting the diagnostic criteria for overt diabetes. The WHO has long distinguished between these two situations and, in 2025, also issued the first separate global recommendations for the care of women with diabetes during pregnancy.
- **Other specific types of diabetes** – especially **monogenic forms** and diabetes due to **damage to or removal of the pancreas**, for example in pancreatitis, cystic fibrosis, or after pancreatectomy.
- **Type 5 diabetes** – a newly classified entity recognized by the IDF in 2025; it is diabetes associated with chronic undernutrition, previously referred to as malnutrition-related diabetes mellitus. Because the official diagnostic criteria are still under development, it is currently a **new, internationally recognized, but still evolving clinical entity**.

# Basic Classification of Diabetes Mellitus

*The clinical category must reflect the pathogenesis.*

| Category | Dominant mechanism | Typical clinical features |
|---|---|---|
| **T1DM** | Autoimmune or idiopathic loss of β-cells → absolute insulin deficiency | more rapid onset, ketosis/DKA, lower C-peptide, autoantibodies |
| **T2DM** | Insulin resistance + progressive β-cell dysfunction | obesity/visceral adiposity, long latent phase, comorbidities |
| **Gestational diabetes** | Pregnancy-induced insulin resistance with insufficient β-cell compensation | diagnosis during pregnancy, risk for both mother and fetus |
| **Other specific types** | Monogenic forms, exocrine pancreas disorders, endocrinopathies, medications, post-transplant diabetes | atypical age, family pattern, pancreatitis, steroids, etc. |

*The most common mistake is the automatic assumption: adult patient = T2DM.*

The basic classification is simple, but its incorrect use leads to incorrect management. In adults in particular, T1DM, LADA, MODY, or pancreatogenic diabetes may be mistakenly classified as T2DM. “Is this patient insulin-resistant, insulin-deficient, or both?” This question is clinically more productive than the label itself.

**Sources:**

ADA. *Diagnosis and Classification of Diabetes*—2026.
ISPAD Clinical Practice Consensus Guidelines 2024: *Screening, Staging, and Strategies to Preserve Beta-Cell Function in T1D*.
WHO. *Diabetes fact sheet*, 2024.

# Diagnostic Criteria for Diabetes and Prediabetes

*Hyperglycemia is diagnosed in the laboratory; the mechanism is determined clinically.*

| Test | Diabetes mellitus | Prediabetes / intermediate dysglycemia |
|---|---|---|
| **HbA1c** | ≥ 6.5% (48 mmol/mol) | 5.7–6.4% |
| **Fasting plasma glucose** | ≥ 7.0 mmol/L (126 mg/dL) | 5.6–6.9 mmol/L |
| **2-h OGTT** | ≥ 11.1 mmol/L (200 mg/dL) | 7.8–11.0 mmol/L |
| **Random glucose + symptoms** | ≥ 11.1 mmol/L | not used |

If hyperglycemia is not unequivocally symptomatic, the diagnosis usually needs to be confirmed by repeat testing.

The diagnostic criteria themselves indicate the presence of dysglycemia, not the type of diabetes. For HbA1c, interpretation may be unreliable in situations such as anemia, hemoglobinopathies, pregnancy, rapid erythrocyte turnover, and certain renal and hepatic conditions. This is of practical importance especially in emergency medicine and in the differential diagnosis of newly detected hyperglycemia.

**Sources:**

ADA. *Diagnosis and Classification of Diabetes*—2026.
IDF Global Clinical Practice Recommendations for Type 2 Diabetes, 2025.
WHO. *Use of Glycated Haemoglobin in the Diagnosis of Diabetes Mellitus*.

# Prediabetes, Glucotoxicity, and Lipotoxicity

*The transition from risk to overt disease*

- Prediabetes is a state in which metabolic dysregulation, endothelial damage, and partial β-cell dysfunction are already present.
- Prediabetes is not just “slightly elevated blood sugar,” but a biological state with real vascular and metabolic consequences.
- **Vicious cycle:** Chronically elevated glucose promotes oxidative stress, AGE formation, PKC activation, and mitochondrial damage.
- Excess free fatty acids and ectopic fat impair insulin signaling and insulin secretion.
- Glucotoxicity and lipotoxicity reinforce each other and create a self-amplifying metabolic loop.
- **Clinical significance:** The earlier the intervention, the greater the chance of slowing or reversing dysglycemia.




*This is where the concept of “metabolic memory” arises: early glycemic control has long-term significance.*

# Type 1 diabetes mellitus

*Model of absolute insulin deficiency and autoimmune β-cell damage.*

genetic susceptibility and triggers

staging from autoimmunity to clinical diabetes

mechanism of DKA as a consequence of absolute insulin deficiency

**Autoimmune T1DM:**

- destruction of beta cells leading to absolute insulin deficiency
- highest incidence in Finland (29.5/100,000) and lowest in Japan (1.6/100,000)

**Idiopathic T1DM:**

- it is not possible to demonstrate the autoimmune nature of beta-cell destruction (more common in Asians and Africans)

## Definition

- **Type 1 diabetes mellitus** is usually an autoimmune disease characterized by T-lymphocyte-mediated destruction of pancreatic β-cells. Its development involves genetic predisposition (HLA-DR3, DR4) and environmental factors. The result is an absolute insulin deficiency, which leads to hyperglycemia, increased lipolysis, and ketogenesis, with diabetic ketoacidosis being a typical complication.

# Immunopathogenesis of T1DM

*From genetic predisposition to β-cell destruction*

- The HLA constellation and other genes affecting antigen presentation and immune tolerance play a key role.
- The autoimmune process leads to the development of islet autoantibodies (IAA, GAD, IA-2, ZnT8) and T-lymphocyte-mediated destruction of β-cells.
- Preclinical stages may last months to years; clinical manifestation occurs only after a critical decline in functional β-cell mass.
- Environmental and infectious triggers are probably important, but in an individual patient their contribution is often difficult to prove.
- The result is an absolute or near-absolute insulin deficiency with a high tendency toward ketogenesis.

**Mechanistic sequence**

genetic susceptibility

loss of tolerance

autoimmune insulitis

β-cell loss

*Autoantibodies are markers of the process; the actual damage is mediated mainly by cellular immune mechanisms.*

## Basic Characteristics

- autoimmune disease
- selective destruction of pancreatic β-cells
- result → absolute insulin deficiency

## Genetic Predisposition

- strong association with:
  - HLA class II:
    - **HLA-DR3**
    - **HLA-DR4**
- genetics ≠ a sufficient cause
  - an **environmental trigger** is also needed

## Triggering Factors (Environmental)

- **viral infections:**
  - Coxsackie B
  - rubella
- **toxins / diet** (under discussion)
- **“hygiene hypothesis”**
- they trigger an **autoimmune response**

**Hygiene Hypothesis (the “Old Friends” Hypothesis)**

- In the context of the development of **type 1 diabetes mellitus (T1DM)**, it is used to explain the sharp increase in autoimmune diseases in developed countries.

➤ **Lack of immune stimulation:** The hypothesis assumes that an overly clean environment and reduced contact with microbes, parasites, and infections in early childhood (due to high hygiene standards, vaccination, and antibiotics) lead to the immune system becoming “bored.”

➤ **Autoimmune reaction:** Because the immune system does not have enough natural pathogens to react to, it becomes hyperactive and begins to “attack” the body’s own tissues—in the case of T1DM, the pancreatic beta cells that produce insulin.

➤ **Increase in cases:** This theory explains why the incidence of T1DM is rising especially in countries with a high standard of living and better hygiene, where contact with certain types of bacteria is limited.

**Hygiene Hypothesis (the “Old Friends” Hypothesis)**

**Related facts:**

- **Gut microbiota:** An imbalance in the gut microbiota plays an important role and may be influenced precisely by the modern lifestyle and the lack of natural microbial stimuli.
- **Protective factors:** Conversely, contact with nature, animals, or infections in childhood may “train” the immune system and act protectively against the development of autoimmunity.
- **Incidence:** Type 1 diabetes has been presenting more frequently in recent years, which supports the hygiene hypothesis as one of the possible causes of this increase.

## Autoimmune Reaction

## Mechanism:

- presentation of β-cell antigens (APCs)
- activation of **T-lymphocytes** (**CD4+**, **CD8+**)
- infiltration of the pancreas → **insulitis**
- cytotoxic damage to β-cells

# Staging of T1DM and the Importance of Screening

*Modern concept: T1DM begins before hyperglycemia*




Screening of at-risk individuals helps reduce DKA at presentation and creates an opportunity for early intervention. Multiple positive autoantibodies significantly increase the likelihood of progression to overt diabetes. The practical importance of screening lies in education, monitoring, and a lower risk of presentation with DKA.

- immunomodulatory approaches, teplizumab in the context of delaying progression in selected at-risk individuals


Pre-T1D
Stage 1
Stage 2
Stage 3
100
0
% β-cell mass/function
Genetic risk
Normal glucose
Dysglycaemia
Clinical disease
B
T
CT
β
Years


STAGE 1
STAGE 2
STAGE 3
Insulin-producing beta cells
Pancreas
CD3 protein
T cells

**Autoantibodies**

- group of antibodies against the pancreatic islets of Langerhans (**ICA**)
  - **anti-GAD65 (GADA)**, antibodies against glutamic acid decarboxylase
  - **anti-IA-2**, antibodies against tyrosine phosphatase
  - **IAA**, insulin autoantibodies
- **anti-ZnT8A**, antibodies against zinc transporter 8

➤ **markers of autoimmunity**

- The prevalence of **anti-GAD** in both pediatric and adult patients with type 1 diabetes is **70–80%**.
- Detection of **anti-GAD** in individuals has a **65–90% sensitivity** for the development of type 1 diabetes within **5–10 years**. With increasing age at the onset of type 1 diabetes, the value of **anti-GAD** increases.
- For prediction of risk for type 1 diabetes, a combination of at least **2 antibodies** is recommended: **GAD and IAA** or **GAD and IA-2A**. The risk of developing type 1 diabetes within **5 years** with the combined presence of **GAD and IAA** is **68%**, and with **GAD and IA-2A** it is **86%**.


Anti-islet autoantibodies
ICA
IAA
GADA
IA-2A
ZnT8A
Diagnosis
Prediction
Pathophysiology
・Immune-mediated
・Idiopathic
・Onset
・Progression
・Insulitis specific
・General autoimmunity

# BETA CELL-SPECIFIC AUTOANTIGENS



## β-Cell Destruction

- progressive loss of cells
- clinical signs appear only when:
    - approximately **80–90% of β-cells** have been destroyed
- development of:
    - hyperglycemia
    - ketogenesis

- At the beginning, insulitis is non-destructive (regulated by Th2 and Th3 lymphocytes).
- Later, under the influence of external factors (stress, infection), Th1 lymphocytes begin to predominate, insulitis becomes destructive, and diabetes develops.
- The factors that trigger the entire autoimmune process may differ from the factors that precipitate the development of destructive insulitis and subsequently diabetes.
- **destructive insulitis** – the cellular type of immune response predominates, mediated by cytotoxic T lymphocytes, NK cells, and macrophages; free oxygen radicals also play a role in the destruction
- **DM becomes clinically manifest after destruction of 80–90% of beta cells** (with destruction of 50–60%, **IFG** or **IGT** may appear)
  - manifestation during puberty (peak at 12 years of age)
  - seasonal pattern
  - long preclinical period

The character of insulitis and the rate of beta-cell destruction vary:

- **Rapidly progressive form of insulitis**
  - in children (but it may also occur in adulthood)
  - insulitis lasts on the order of weeks to months
  - progresses to destruction of most beta cells
  - onset of diabetes is dramatic, with classic symptoms
  - tendency to develop ketoacidosis
  - need for insulin therapy from the onset of the disease

- **Slowly progressive form of insulitis**
  - insulitis lasts for years to decades
  - manifestation of diabetes in adulthood
  - **LADA** (*latent autoimmune diabetes in adults*)
  - does not present with the typical symptoms of type 1 diabetes
  - no tendency toward ketoacidosis
  - frequently mistaken for type 2 diabetes – leading to inappropriate treatment with diet alone and **oral antidiabetic drugs (OADs)** – with apparently satisfactory control due to the persistence of some minimal insulin secretion (beta cells are destroyed more slowly)
  - also requires insulin treatment

## Metabolic Consequences

- **1. ↓ insulin → ↓ glucose utilization**
- muscle, fat → “cellular starvation”
- **2. ↑ gluconeogenesis (liver)**
- further increases blood glucose
- **3. lipolysis**
- ↑ free fatty acids
- **4. ketogenesis**
- formation of ketone bodies → **ketoacidosis**


Liver
↓Insulin
↑Glucagon
Diabetic
Pancreas
↑glycogen breakdown
↑glucose synthesis
↑ketone formation
acetoacetate β - OHB
β - oxidation
↑Glucagon
↓Insulin
Fat
↑FAs
↑lipolysis
↑ketones & glucose
in bloodstream
glycogen
glucose
ketones
Kidney
hyperglycemia
excessive glucose excretion
osmotic diuresis
volume depletion

## Diabetic Ketoacidosis (DKA)

- typical of **type 1 diabetes**
- **mechanism:**
  - ↓ insulin
  - ↑ glucagon
- **result:**
  - metabolic acidosis
  - dehydration
  - Kussmaul respiration

# Why DKA Develops: Pathophysiological Logic

*Absolute insulin deficiency + excess counterregulatory hormones*

- insulin suppresses catabolism
- Insulin deficiency removes the inhibition of lipolysis, proteolysis, and hepatic gluconeogenesis; glucagon, catecholamines, cortisol, and GH further amplify the process.
- Free fatty acids are oxidized in the liver to ketone bodies; once buffering capacity is exceeded, metabolic acidosis develops.
- Hyperglycemia causes osmotic diuresis, dehydration, and loss of sodium, potassium, and other electrolytes.
- Total body potassium deficit may be substantial even when serum potassium is initially normal or elevated.
- Triggers may include infection, omission of insulin, first manifestation of T1DM, myocardial infarction, pregnancy, or SGLT2 inhibitor-associated euglycemic DKA.

**Vicious cycle of DKA**

↓ insulin

↑ lipolysis

↑ ketone bodies

acidosis + dehydration

*The patient does not die from hyperglycemia itself, but from the combination of acidosis, dehydration, hyperosmolality, and electrolyte disturbances. Emphasis should be placed on the risk of an apparently normal serum potassium level.*

*In DKA, we treat three problems at once: volume depletion, insulin deficiency, and electrolyte losses.*

# Type 2 diabetes mellitus

*Heterogeneous syndrome combining insulin resistance and progressive β-cell dysfunction.*

- muscle, liver, adipose tissue, and the β-cell
- incretin system, kidneys, and CNS
- why T2DM is not just a consequence of obesity

*Different patients may have different proportions of insulin resistance and β-cell failure. This explains the differing clinical phenotype as well as the differing response to treatment.*

## Definition

- **Type 2 diabetes mellitus** is a metabolic disease characterized by a combination of insulin resistance and relative insulin deficiency. Insulin resistance arises mainly in skeletal muscle, adipose tissue, and the liver, and is closely linked to obesity and chronic inflammation. Initially, compensatory hyperinsulinemia develops, but this is gradually followed by β-cell dysfunction as a result of gluco- and lipotoxicity, leading to the development of hyperglycemia.

# T2DM as a Heterogeneous Multisystem Disease

*Not a single disease, but a shared phenotype of several disorders*

**Pathophysiological mechanism:** insulin resistance and beta-cell dysfunction

- the most common type of diabetes
- prevalence is higher in Black people, Japanese people, and Pacific populations than in White people
- prevalence in developed countries continues to rise – a diabetes epidemic
- unhealthy lifestyle (overeating, physical inactivity, obesity)
- poorer and less educated populations in developed countries
- highest prevalence – North American Pima Indians (80% of the population)

**Risk factors:**

- genetic predisposition (more significant than in type 1 diabetes)
- obesity – the most important risk factor (obese individuals have a 10× higher risk than non-obese individuals)
- lifestyle (inactivity, overeating)
- older age

**Heredity:**

- concordance in monozygotic twins is 80%; risk for a first-degree relative is 10–15%
- more frequent occurrence in women with previous gestational diabetes and in individuals with hypertension and dyslipidemia

*T2DM should be understood as a process of adaptation and subsequent decompensation of the beta cell.*

# T2DM as a Heterogeneous Multisystem Disease

*Not a single disease, but a shared phenotype of multiple disorders*

- T2DM develops when the β-cell can no longer compensate for insulin resistance over the long term.
- Some patients have predominant visceral adiposity and insulin resistance, while others have relatively early β-cell failure.
- Ectopic fat deposition, low-grade inflammation, mitochondrial dysfunction, and disturbances of the gut–brain axis also play an important role.
- In clinical practice, T2DM therefore often coexists with MASLD, hypertension, dyslipidemia, CKD, and cardiovascular disease.
- The pathophysiology develops over years to decades before diabetes is actually detected in outpatient care (the β-cell must increase insulin secretion over the long term to overcome peripheral resistance. When this compensatory capacity fails, hyperglycemia appears; this is a time-dependent process: initially the organism compensates, later it decompensates.)

**Dominant axes of T2DM**

- insulin resistance
- β-cell insufficiency
- ectopic fat
- cardiorenal-metabolic associations

*T2DM should be understood as a process of adaptation followed by β-cell decompensation.*

# Skeletal Muscle Insulin Resistance

*Why postprandial glycemia rises*

- Skeletal muscle is the largest target organ for postprandial glucose utilization.
- In insulin resistance, GLUT4 translocation decreases and the ability of muscle cells to store glucose as glycogen is reduced.
- Contributing factors include ectopic intramyocellular lipids, ceramides, inflammatory signals, physical inactivity, and mitochondrial dysfunction.
- The result is more pronounced postprandial hyperglycemia and, secondarily, a higher insulin requirement.
- Exercise improves glucose uptake partly through insulin-independent mechanisms, which is why it has exceptional pathophysiological significance.

**Muscle in T2DM**

- ↓ GLUT4
- ↓ glycogen synthesis
- ↑ lipid intermediates
- preserved response to exercise

why physical activity has an effect even in marked insulin resistance

# Hepatic Insulin Resistance

*Why fasting glycemia is elevated*

- Under normal insulin action, the liver suppresses gluconeogenesis and glycogenolysis.
- In hepatic insulin resistance, the liver continues to produce glucose even in situations when it should be “switched off.”
- Important contributing factors are the supply of substrates from lipolysis and proteolysis, hyperglucagonemia, and steatotic overload of the liver.
- Selective hepatic insulin resistance helps explain parallel hyperglycemia together with persistent lipogenesis.
- Clinically, this leads to elevated fasting glycemia, MASLD, and impaired metabolic flexibility.

**Liver in T2DM**

↑ gluconeogenesis

↑ glycogenolysis

hyperglucagonemia

steatosis and de novo lipogenesis

*Metformin primarily targets hepatic glucose production – its therapeutic relevance follows directly from the pathophysiology.*

# Dysfunction of Adipose Tissue and Adiposopathy

*Fat as an endocrine and inflammatory organ*

- Visceral adipose tissue is not an inert energy store; it is an active endocrine and immunologic organ.
- With adipocyte hypertrophy, lipolysis increases, along with the release of free fatty acids, TNF-α, IL-6, and other inflammatory mediators.
- The protective effect of adiponectin decreases, and the storage of fat in a “safe” depot worsens.
- Excess energy is then redistributed ectopically to the liver, muscles, pancreas, and heart.
- Adiposopathy explains why the quality and distribution of fat may be more important than BMI alone.




*Visceral fat is metabolically more dangerous than subcutaneous fat because it produces more inflammatory and lipotoxic signals. Adiposopathy is the mechanistic bridge between obesity and diabetes and the reason why reducing visceral fat leads to improved insulin sensitivity.*

*Visceral adiposity correlates with metabolic risk better than total body weight alone.*


Obesity
Skeletal Muscle
-Increased FFA uptake
-Increased extramyocellular adipose
-Macrophage activation/recruitment
-ER stress
Adipose
-Adipocyte hypertrophy
-Macrophage recruitment
-Macrophage polarity switch
-Increased cytokine production
-Increased lipolysis
-ER stress
Liver
-Increased lipid content
-Steatosis
-Kupffer cell activation/recruitment
-Increased cytokine production
-ER stress
IR
IR
IR
Systemic Insulin Resistance and Inflammation
endocrine crosstalk

# β-Cell Failure and Incretin Dysfunction

*Why compensation is no longer sufficient*

- At first, the β-cell tries to compensate for insulin resistance with hyperinsulinemia, but later its functional reserve becomes exhausted.
- Glucotoxicity, lipotoxicity, amyloid deposition, oxidative stress, ER stress, and β-cell dedifferentiation all contribute.
- The incretin effect is weakened in T2DM; postprandial insulin secretion is inadequate and the glucagon response is insufficiently suppressed.
- Relative hyperglucagonemia further promotes hepatic glucose production.
- When β-cell compensation fails, the transition from insulin resistance to overt diabetes occurs.

**Points of β-cell failure**

- first-phase secretion disappears
- inkretínový efekt slabne
- glucagon is not suppressed
- progressive insulinopenia

*GLP-1 receptor agonists and dual incretin drugs improve some of these mechanisms precisely because they target the incretin and satiety axis.*

*Long-standing T2DM often involves more marked insulinopenia than is clinically assumed.*

## β-Cell Dysfunction

**Mechanisms:**

- glucotoxicity
- lipotoxicity
    - oxidative stress
    - amyloid (IAPP) deposition in the islets

**Progressively:**

- ↓ insulin secretion
- loss of first-phase secretion


First phase
Insulin release
Second phase
Insulin release
NO DIABETES
EARLY TYPE 2
LATE TYPE 2
FOOD CONSUMED

**Typical course of type 2 diabetes.**
The development of type 2 diabetes is associated with dysfunction of pancreatic β-cells and insulin resistance. Overeating and/or obesity lead to the development of insulin resistance, and normal β-cells secrete larger amounts of insulin to compensate for the increased insulin resistance. Subsequently, large adipocytes release greater amounts of free fatty acids and/or various inflammatory cytokines, which progressively worsen β-cell function and ultimately lead to the onset of diabetes. This process is known as **β-cell lipotoxicity**. Once hyperglycemia appears, β-cell function progressively deteriorates; insulin biosynthesis and secretion decline. This process is known as **β-cell glucotoxicity**, which is often observed in type 2 diabetes.




*World J Diabetes* 2013; 4(6): 263-269

# “Ominous Octet” in Modern Interpretation

*T2DM goes beyond the pair of insulin resistance + β-cell failure*




Additional players are the **gut, kidneys, and CNS** – which is why modern therapy targets more than one organ at a time.
**From Octet to "Egregious Eleven":** also inflammation, immune system dysfunction, and imbalance of the gut microbiota.

*T2DM is not a linear disorder, but a network dysregulation. That is why monotherapy often fails over time, and combination treatment makes biological sense.*

# Genetics, Environment, Youth-Onset T2DM, and Pregnancy

*Same phenotype, different entry pathways*

### Genetics and environment

- Polygenic predisposition modulates both β-cell susceptibility and insulin sensitivity.
- Urbanization, sedentary lifestyle, energy-dense diet, sleep deprivation, and social determinants alter risk exposure.
- Epigenetic changes may explain the intergenerational transmission of risk.

### Youth-onset T2DM and GDM

- T2DM in adolescents tends to be more aggressive, with a faster decline in β-cell function.
- In pregnancy, placental hormones increase insulin resistance; if the β-cell fails to compensate, gestational diabetes develops.
- GDM increases the risk of T2DM in the mother as well as metabolic risk in the offspring.

*T2DM and GDM are biologically interconnected through insulin resistance, β-cell reserve, and fetal programming.*

## Gestational DM and Diabetes Detected During Pregnancy

- The **WHO distinguishes between gestational diabetes mellitus** and **diabetes in pregnancy**.
- **Gestational diabetes** means hyperglycemia above normal, but below the diagnostic threshold for overt diabetes.
- **“Diabetes in pregnancy”** refers to a situation in which the diagnostic criteria for diabetes mellitus as such are already met during pregnancy.
- This distinction is also important prognostically, because women after gestational diabetes have an increased risk of subsequent development of **type 2 diabetes**.

### Other Specific Types of Diabetes

- **monogenic diabetes** – rarer forms caused by a change in a single gene. Clinically, the most important forms are **MODY** and **neonatal diabetes mellitus**. They are often mistakenly classified as type 1 or type 2 diabetes, although the correct genetic diagnosis can fundamentally change both treatment and prognosis.
- **diabetes due to damage to or removal of the pancreas**. It develops in pancreatitis, cystic fibrosis, after surgical removal of the pancreas, or in other pancreatic diseases. The pathomechanism is that the damaged pancreas produces less insulin, which leads to hyperglycemia. For a dentist, it is important to consider this group especially in polymorbid patients with a gastroenterological or surgical history.

## Other Specific Types of Diabetes and Mechanisms of Acute Decompensation

*Thinking mechanistically means not overlooking unusual diabetes*

### Other specific types

- **Monogenic forms (MODY)** – a β-cell disorder with a typical familial pattern.
- **Pancreatogenic diabetes** – after pancreatitis, resection, cystic fibrosis, or pancreatic tumor.
- **Endocrinopathies and drugs** – glucocorticoids, Cushing syndrome, acromegaly, transplantation.

### Hypoglycemia and HHS

- **Hypoglycemia** is the result of a relative or absolute excess of insulin in relation to the current needs of the tissues (neuroglycopenia and the autonomic response are key pathophysiological phenomena).
- **HHS** develops in severe hyperglycemia and dehydration, when residual insulin still prevents massive ketogenesis.
- Neurological symptoms in **HHS** are caused mainly by hyperosmolality.

*If the clinical picture does not "fit," the diabetes classification and precipitating factors should be reassessed.*

## Type 5 Diabetes – a New Entity

- the international recognition of **type 5 diabetes** – according to the IDF, this is diabetes associated with **chronic undernutrition**, especially in childhood and adolescence, followed by insufficient pancreatic development. Pathomechanistically, it is neither a typical autoimmune process as in type 1 diabetes nor predominantly insulin resistance as in type 2 diabetes; rather, the core problem is **insulin deficiency caused by underdeveloped pancreatic tissue**.
- this form is typically described in **lean adolescents and young adults** in low- and middle-income countries. IDF diagnostic criteria have not yet been standardized, and that is why, in 2025, a working group was established to develop formal recommendations. It is therefore a **new and relevant, but still methodologically unfinished classification category**.

## Prediabetes

- **clinically significant**, an intermediate stage between normal glucose homeostasis and diabetes
- pathophysiologically, it most often represents an early manifestation of insulin resistance and an insufficient compensatory response of β-cells
- the **WHO** explicitly identifies **impaired fasting glycaemia** and **impaired glucose tolerance** as intermediate states associated with an increased risk of progression to **type 2 diabetes**

## Diagnostic Criteria

- According to the **ADA 2026**, diabetes can be diagnosed on the basis of **HbA1c** or **plasma glucose**. The basic thresholds include **fasting glucose ≥ 126 mg/dL (7.0 mmol/L)**, **2-hour glucose during a 75 g OGTT ≥ 200 mg/dL (11.1 mmol/L)**, **HbA1c ≥ 6.5%**, or **random plasma glucose ≥ 200 mg/dL (11.1 mmol/L)** in the presence of typical symptoms of hyperglycemia or a hyperglycemic crisis.
- For **prediabetes**, the ADA states a **fasting glucose of 100–125 mg/dL (5.6–6.9 mmol/L)**.

## Relevance for Dentistry

- diabetes — also as a **disease with significant oral manifestations** — is associated with a higher risk of **periodontitis**, slower healing, **xerostomia**, and **candidiasis**. Elevated blood glucose and dry mouth additionally increase the risk of caries and infectious complications
- the relationship between diabetes and periodontal disease is bidirectional: poor periodontal health may make glycemic control more difficult
- in cases of recurrent periodontitis, impaired healing after extractions, frequent fungal infections, or marked xerostomia, the dentist should also consider a possible disorder of glucose metabolism
- in outpatient practice, the aim is not to establish the diagnosis of diabetes, but to correctly identify the at-risk patient and refer them early for internal medicine or diabetology assessment

## Conclusion

- **Diabetes mellitus is not a single disease, but a group of pathophysiologically distinct conditions** that lead to the common phenotype of chronic hyperglycemia.
- The classical classification into **type 1 diabetes, type 2 diabetes, gestational diabetes, and other specific types** remains the foundation of clinical thinking in 2026. A new element is **type 5 diabetes**, which reflects the importance of undernutrition and global health inequalities in the pathogenesis of diabetes.
- For **dentistry**, it is essential to understand that diabetes significantly affects **periodontal status, healing, and infectious morbidity in the oral cavity**, and therefore belongs among the diagnoses that a dentist must always keep in mind.

# Chronické komplikácie

*Spoločné mechanizmy, odlišné orgánové fenotypy poškodenia.*

- endotel, oxidatívny stres a AGE
- mikrovaskulárne vs. makrovaskulárne komplikácie
- prečo komplikácie začínajú skôr, než ich klinicky zachytíme

## Patofyziologické mechanizmy chronických komplikácií diabetu

Chronické komplikácie diabetu vznikajú ako dôsledok **dlhodobej hyperglykémie**, **glykemickej variability** a pri DM 2. typu aj **inzulínovej rezistencie, lipotoxicity a chronického subklinického zápalu**. Spoločným menovateľom je **nadprodukcia reaktívnych foriem kyslíka (ROS)** a následná aktivácia viacerých poškodzujúcich metabolických dráh. diabetesjournals.... +2

**Hlavné mechanizmy:**

- **Polyolová dráha**: nadbytok glukózy sa mení na sorbitol, spotrebúva sa NADPH, klesá antioxidačná kapacita bunky a rastie osmotický aj oxidačný stres. PMC +1
- **Tvorba AGE produktov a aktivácia RAGE receptorov**: neenzýmová glykácia bielkovín, lipidov a nukleových kyselín vedie k poruche funkcie proteínov, k zosieťovaniu extracelulárnej matrix, k zápalu a k poškodeniu endotelu. diabetesjournals.... +2
- **Aktivácia PKC**: mení vaskulárnu permeabilitu, vazomotoriku, produkciu cytokínov, adhéziu leukocytov, angiogenézu a prispieva k mikrovaskulárnemu poškodeniu. Nature +1
- **Hexózamínová dráha**: mení génovú expresiu a podporuje prozápalové a profibrotické odpovede. PMC +1
- **Oxidačný stres, mitochondriálna dysfunkcia a zápal**: tieto deje prepájajú vyššie uvedené dráhy a vedú k endoteliálnej dysfunkcii, fibrotizácii a progresii orgánového poškodenia. PubMed +2

**Kľúčový cievny následok** je **endoteliálna dysfunkcia**: klesá biodostupnosť NO, rastie permeabilita cievnej steny, aktivujú sa prozápalové a protrombotické mechanizmy, zhrubujú sa bazálne membrány a zhoršuje sa mikrocirkulácia. Súčasne sa uplatňuje aj fenomén **metabolickej pamäte**, teda pretrvávanie poškodenia aj po neskoršom zlepšení glykémie. Nature +2

# Spoločné mechanizmy diabetických komplikácií

*Jedna hyperglykémia, viacero poškodzujúcich dráh*

- Chronická hyperglykémia zvyšuje tok cez polyolovú dráhu, tvorbu AGE, aktiváciu PKC a hexosamínovej dráhy.
- Následkom sú oxidačný stres, endotelová dysfunkcia, prozápalové prostredie a poškodenie mikrocirkulácie.
- Dôležitý je aj synergický vplyv hypertenzie, dyslipidémie, albuminúrie, fajčenia a prokoagulačného stavu.
- „Metabolická pamäť“ vysvetľuje, prečo skorá dobrá kontrola prináša dlhodobý benefit aj po rokoch.
- Komplikácie sa nevyvíjajú izolovane; pacient často nesie simultánne mikrovaskulárne aj makrovaskulárne poškodenie.

**Hlavné poškodzujúce dráhy**

- AGE
- PKC
- oxidatívny stres
- endotelová dysfunkcia

Vysoká glykémia je dôležitá, no sama nepostačuje – riziko určuje celý kardiorenálno-metabolický profil.

# Diabetické ochorenie obličiek (DKD)

*Glomerulárna hyperfiltrácia, zápal, fibrogenéza*

- Včasnou zmenou môže byť glomerulárna hyperfiltrácia a intraglomerulárna hypertenzia.
- Hyperglykémia, RAAS aktivácia, tubuloglomerulárna dysregulácia a SGLT2-dependentná reabsorpcia podporujú progresiu poškodenia.
- Následne sa rozvíja albuminúria, pokles eGFR, tubulointersticiálny zápal a fibrogenéza.
- DKD nie je len glomerulopatia; ide o kombinované glomerulárne, tubulárne, vaskulárne a zápalové poškodenie.
- Preto je ochrana obličky viazaná na glykémiu, tlak, RAAS blokádu a dnes aj na SGLT2 inhibítory a ďalšie nefroprotektívne stratégie.



# Diabetická retinopatia

*Mikrovaskulárne a neurodegeneratívne poškodenie sietnice*

- Chronická hyperglykémia vedie k strate pericytov, poškodeniu kapilárnej steny a zvýšenej priepustnosti hemato-retinálnej bariéry.
- Vznikajú mikroaneuryzmy, ischemické zóny, edém a v pokročilom štádiu patologická neovaskularizácia cez VEGF signál.
- Retinopatia nie je len vaskulárna choroba; prítomná je aj neurodegenerácia a glióza.
- Riziko rastie s dĺžkou diabetu, hyperglykémiou, hypertenziou, graviditou a renálnym poškodením.
- Náhla rýchla korekcia glykémie môže prechodne zhoršiť nález, preto treba pacientov starostlivo monitorovať.

**Sietnica pri diabete**

pericyty ↓ (poškodenie kapilár)

bariéra poškodená (zvýšenie priepustnosti hemato-retinálnej bariéry)

ischemia + VEGF

edém / neovaskularizácia

Klinická pointa: mikrovaskulárne komplikácie sú často bez príznakov, kým nie sú pokročilé.

# Diabetická neuropatia a diabetická noha

*Nerv, mikrocirkulácia, imunita a mechanické zaťaženie*

- Periférna neuropatia vzniká pôsobením hyperglykémie, dyslipidémie, oxidačného stresu, mitochondriálnej poruchy a ischémie nervu.
- Poškodenie citlivosti zvyšuje riziko nepozorovaných mikrotraumat, deformít, tlakového poškodenia a ulcerácií.
- Autonómna neuropatia zhoršuje potenie, vazomotoriku, GI motilitu, sexuálnu funkciu aj kardiovaskulárnu odpoveď.
- Pri diabetickej nohe sa spája neuropatia, ischémia, porucha hojenia a vyššia náchylnosť na infekciu.
- Prevencia stojí na kontrole rizikových faktorov, pravidelnom vyšetrení nôh a včasnom zachytení ulcerácie.

**Cesta k ulcerácii**

senzorická strata

deformita / tlak

porucha hojenia

infekcia a amputácia

# Makrovaskulárne ochorenie pri diabete

*Ateroskleróza, trombóza a endoteliálna dysfunkcia*

- Diabetes urýchľuje aterogenézu kombináciou hyperglykémie, dyslipidémie, zápalu, endoteliálnej dysfunkcie a prokoagulačného stavu.
- Typická je aterogénna dyslipidémia: vysoké TG, nízke HDL a vyšší podiel malých denzných LDL častíc.
- Chronická hyperinzulinémia a inzulínová rezistencia podporujú hypertenziu, sympatikovú aktiváciu a vaskulárnu rigiditu.
- Výsledkom je vyššie riziko ICHS, cievnej mozgovej príhody, periférneho artériového ochorenia a náhlej smrti.
- Preto moderný manažment DM cieli nielen HbA1c, ale aj tlak, lipidy, hmotnosť a renálne riziko.

**Aterotrombotický profil**

endotel poškodený

atherogénne lipoproteíny

zápal a trombóza

ISCHEMICKÉ príhody

Diabetik neumiera najčastejšie na hyperglykémiu, ale na jej orgánové následky.

# Srdcové zlyhávanie, MASLD, infekcie a kognícia

*Diabetes je ochorenie orgánovej zraniteľnosti*

## Kardio-hepatálne dôsledky

- Diabetes zvyšuje riziko srdcového zlyhávania aj bez preukázanej ICHS.
- Môže sa uplatniť diabetická kardiomyopatia, porucha energetiky myokardu a intersticiálna fibróza.
- MASLD predstavuje pečeňový fenotyp systémovej inzulínovej rezistencie.

## Imunita a CNS

- Hyperglykémia zhoršuje funkciu neutrofilov, hojenie a obranyschopnosť proti infekcii.
- Vyššie je riziko ťažšieho priebehu infekcií kože, močových ciest aj systémových infekcií.
- Dlhodobá dysglykémia súvisí aj s kognitívnym poklesom a cerebrálnym vaskulárnym poškodením.

Pri modernom manažmente DM musíme myslieť ďalej než na „klasické triády“ komplikácií.

# Gravidita, placenta a fetálne programovanie

*Prečo je diabetes v gravidite dôležitý pre dve generácie*

- Materská hyperglykémia zvyšuje fetálnu expozíciu glukóze; plod reaguje hyperinzulinémiou a rastovým stimulom.
- Následkom môže byť makrozómia, dystokia ramien, novorodenecká hypoglykémia a metabolická vulnerabilita.
- Pri pregestačnom diabete rastie riziko kongenitálnych malformácií, ak je glykemická kontrola v čase organogenézy zlá.
- Placenta je aktívny endokrinný orgán zvyšujúci inzulínovú rezistenciu matky v druhej polovici gravidity.
- GDM je marker budúceho diabetu a kardiometabolického rizika matky aj potomstva.




*Transgeneračný efekt - inzulín matky placentou neprechádza, ale glukóza áno. Plod teda odpovedá vlastným inzulínom, čo podporuje rast a ukladanie tuku. Ak ide o pregestačný DM so zlou kompenzáciou v období organogenézy, vzniká navyše riziko malformácií.*

# Liečba prepojená s patofyziológiou

*Terapia je najúčinnejšia vtedy, keď cieli dominantný mechanizmus ochorenia.*

- hmotnosť a energetický balans
- liek podľa orgánu a rizika
- technológie a nemocničná starostlivosť

Terapia viazaná na orgán alebo proces: pečeň, oblička, inkretínová os, inzulínopénia, hmotnosť, kardiorenálne riziko.

# Životný štýl a redukcia hmotnosti ako patofyziologická liečba

*Energetická bilancia je upstream zásah*

- Redukcia hmotnosti znižuje viscerálnu adipozitu, ektopický tuk v pečeni a pankrease a zlepšuje inzulínovú senzitivitu.
- Fyzická aktivita zlepšuje využitie glukózy v svale, kardiorespiračnú zdatnosť, krvný tlak a tukový profil.
- Dietárne intervencie sa môžu líšiť, ale rozhodujúci je dlhodobý energetický deficit a udržateľnosť.
- U časti pacientov môže intenzívna redukcia hmotnosti viesť k remisii T2DM, najmä pri kratšom trvaní ochorenia.
- Patofyziologicky ide o zásah do samotného zdroja preťaženia, nie iba o symptomatickú korekciu glykémie.

**Čo sa zlepší po úbytku hmotnosti**

- viscerálny tuk ↓
- pečeňový tuk ↓
- inzulínová citlivosť ↑
- β-bunková záťaž ↓

Redukcia hmotnosti nepôsobí len cez nižší príjem kalórií, ale biologicky mení tok substrátov medzi orgánmi. Klesá prísun voľných mastných kyselín, zmenšuje sa hepatálna steatóza a β-bunka je menej nútená k hypersekrečnej kompenzácii.

Remisia T2DM nie je „vyliečenie“, ale dôkaz, že časť patofyziológie je reverzibilná.

# Triedy antidiabetík podľa mechanizmu účinku

*Nepamätať ako zoznam – spájať s orgánom a patofyziológiou*

| Trieda | Hlavný mechanizmus | Patofyziologický zmysel |
|---|---|---|
| Metformín | zníženie hepatálnej produkcie glukózy | cieľ na pečeň a glykémiu nalačno |
| GLP-1 RA / duálne inkretíny | inkretínový efekt, satieta, úbytok hmotnosti, glukagón ↓ | β-bunka, CNS, hmotnosť, kardiometabolický benefit |
| SGLT2 inhibítory | glykozúria, natriuréza, tubuloglomerulárny efekt | obličky, srdcové zlyhávanie, CKD |
| Sulfonylurey / meglitinidy | stimulácia sekrécie inzulínu | užitočné pri inzulínopénii, ale vyššie riziko hypoglykémie |
| Tiazolidíndióny | zlepšenie inzulínovej senzitivity cez PPARγ | cieľ najmä na periférnu rezistenciu |
| Inzulín | náhrada absolútneho alebo relatívneho deficitu | nevyhnutný pri T1DM a pri pokročilej inzulínopénii |

*Na ktorý orgán pôsobí, ktorý defekt koriguje a aké orgánové benefity navyše prináša. Moderné algoritmy už nie sú striktne glukocentrické. Napríklad SGLT2 inhibítory alebo GLP-1 receptorové agonisty volíme aj kvôli srdcu, obličke a hmotnosti.*

Výber lieku sa dnes riadi nielen HbA1c, ale aj ASCVD, HF, CKD, hmotnosťou, rizikom hypoglykémie a preferenciami pacienta.

# Inzulín ako fyziologická substitúcia

*Bazálna, prandiálna a korekčná zložka*

- Pri T1DM je inzulín život zachraňujúca hormonálna substitúcia; pri T2DM sa pridáva pri progresívnej inzulínopénii alebo pri akútnej dekompenzácii.
- Bazálny inzulín kryje hepatálnu produkciu glukózy medzi jedlami a v noci.
- Prandiálny inzulín má napodobniť rýchlu postprandiálnu sekréciu a potlačiť glykemické vzostupy po jedle.
- Nesprávne načasovanie alebo nepomer dávky vedú k hyperglykémii, hypoglykémii a zvýšenej variabilite.
- Edukačný kľúč: inzulín treba chápať ako dynamický systém viazaný na jedlo, pohyb, chorobu a stres.

**Fyziologický model**

- bazálna potreba
- jedlové bolusy
- korekčné dávky
- citlivosť sa mení v čase

Najčastejším omylom je učiť inzulín len ako „dávku“, nie ako model fyziológie.

# CGM, inzulínové pumpy a AID systémy

*Technológia mení nielen monitoring, ale aj patofyziologickú kontrolu ochorenia*

- Kontinuálne monitorovanie glukózy (CGM) umožňuje zachytiť čas v cieľovom rozmedzí, variabilitu a skryté hypoglykémie.
- Inzulínové pumpy a hybridné uzavreté okruhy zlepšujú dávkovanie inzulínu podľa reálneho trendu glukózy.
- V T1DM dnes technológia cieli nielen HbA1c, ale predovšetkým zníženie variability a hypoglykémií.
- Aktuálne odporúčania rozširujú skoré používanie CGM a AID aj na širšie skupiny pacientov na inzulíne.
- Patofyziologicky ide o snahu priblížiť liečbu dynamike zdravej β-bunky, ktorú žiadny statický režim nedokáže dokonale nahradiť.

*už nejde len o „predpísanie inzulínu“, ale o riadenie dynamického systému*

**Čo technológia prináša**

- trend, nie len jednorazová hodnota
- time in range
- menej hypoglykémií
- adaptívne dávkovanie

Aktuálne ADA 2026 zdôrazňujú širšiu dostupnosť CGM/AID skôr v priebehu ochorenia.

# Stresová hyperglykémia a diabetes v nemocnici

*Akútne ochorenie mení potrebu inzulínu aj rizikový profil*

- Akútny stres, sepsa, infarkt, chirurgia a glukokortikoidy zvyšujú hladiny kontraregulačných hormónov a inzulínovú rezistenciu.
- Aj pacient bez známeho diabetu môže mať v nemocnici významnú hyperglykémiu; tá zhoršuje výsledky liečby a prognózu.
- Cieľom nemocničnej liečby je vyhnúť sa extrémom – ťažkej hyperglykémii aj hypoglykémii.
- Perioperačne, pri NPO režime a na JIS treba myslieť na meniace sa potreby inzulínu a tekutín.
- DKA a HHS sú urgentné stavy vyžadujúce protokolizovaný prístup s dôrazom na objem, elektrolyty a inzulín.

**Nemocničná dynamika**

stresové hormóny ↑

inzulínová potreba ↑

NPO / steroidy / infekcia

riziko hypa pri zlepšení stavu

# Kazuistika 1: manifestácia T1DM u mladého pacienta

*Ako zo symptómov odvodiť mechanizmus*

### Anamnéza a nález

- 19-ročný muž
- 2 týždne polyúria, polydipsia, schudol 6 kg
- nauzea, vracanie, acetónový dych
- tachykardia, suché sliznice

### Laboratórium

- glykémia 26 mmol/l
- pH 7,12; $HCO_3^-$ 9 mmol/l
- ketóny pozitívne
- $K^+$ 5,1 mmol/l, ale celkový deficit pravdepodobný

### Diskusné otázky

- Ktorý hormón chýba absolútne?
- Prečo je prítomná acidóza?
- Prečo je $K^+$ sérovo niekedy normálny/vysoký?
- Aké budú prvé tri liečebné kroky?

*Absolútny deficit inzulínu spustil lipolýzu a ketogenézu; acidóza spolu s hyperglykémiou vyvolala osmotickú diurézu a dehydratáciu; sérový draslík je klamlivý, lebo celkové zásoby sú vyčerpané. Navrhovaný postup: tekutiny, monitorovanie a korekcia elektrolytov, inzulín.*

# Kazuistika 2: T2DM s kardiorenálno-metabolickým rizikom

*Neurčujeme iba „cukor“, ale dominantné osi poškodenia*

## Anamnéza a nález

- 62-ročná žena, BMI 34 kg/m$^2$
- HT, dyslipidémia, MASLD, dyspnoe NYHA II
- albuminúria, eGFR 58 ml/min/1,73 m$^2$
- HbA1c 8,4 %

## Patofyziologické osi

- viscerálna adipozita a IR
- hepatálna produkcia glukózy
- renálne a kardiálne riziko
- pravdepodobná progresívna β-bunková insuficiencia

## Diskusné otázky

- Ktoré orgány treba chrániť prioritne?
- Ktoré liekové triedy majú organoprotektívny zmysel?
- Prečo nestačí „len znížiť HbA1c“?
- Ako vysvetliť úlohu redukcie hmotnosti?

*Prioritou je orgánová ochrana, redukcia hmotnosti a liek s benefitom pre srdce/obličku.*

# „Take-home messages“

- T1DM = autoimunitná strata β-buniek a absolútny deficit inzulínu; T2DM = kombinácia inzulínovej rezistencie a progresívneho β-bunkového zlyhania.
- Glykémia nalačno je silno viazaná na pečeň; postprandiálna glykémia na β-bunku, inkretíny a sval.
- DKA vzniká z absolútnej inzulínopénie; HHS z ťažkej hyperglykémie a dehydratácie pri zachovanej reziduálnej inhibícii ketogenézy.
- Mikrovaskulárne a makrovaskulárne komplikácie zdieľajú spoločné mechanizmy, ale každý orgán má vlastný fenotyp poškodenia.
- Moderná liečba DM je kardiorenálno-metabolická a patofyziologicky cielená, nie iba glukocentrická.



# Vybrané odporúčané zdroje

*Primárne texty pre ďalšie štúdium a prípravu prednášky*


1. ADA Professional Practice Committee. Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1).
2. ADA PPCD. 2. Diagnosis and Classification of Diabetes. Standards of Care in Diabetes—2026.
3. ADA PPCD. Sections 7, 9, 10, 11, 12, 15, 16. Standards of Care in Diabetes—2026.
4. IDF Diabetes Atlas, 11th edition, 2025.
5. WHO. Diabetes fact sheet. Updated 14 November 2024.
6. Abel ED et al. Diabetes mellitus—Progress and opportunities in the evolving epidemic. Cell. 2024.
7. Lu X et al. Type 2 diabetes mellitus in adults: pathogenesis, diagnosis, and treatment. Signal Transduct Target Ther. 2024.
8. Pathophysiology and Treatment of Prediabetes and Type 2 Diabetes. Diabetes Care. 2024.
9. Haller MJ et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in T1D.
10. Phillip M et al. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care. 2024.
11. Umpierrez GE et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024.
12. Recent reviews on DKD, diabetic retinopathy and diabetic neuropathy (2024–2026).

# Teplizumab a diabetes mellitus - Anti-CD3 (T-lymfocyty) – „reset imunity“

- moderná imunomodulačná liečba určená pre T1DM
- nejde o klasickú antidiabetickú liečbu (ako inzulín), ale o zásah do samotného autoimunitného procesu
- Teplizumab je monoklonálna protilátka proti CD3 receptoru na T-lymfocytoch:
  - moduluje aktivitu T-buniek → „vyčerpanie“ autoreaktívnych CD8+ + ↑ Treg
  - tlmí autoimunitnú deštrukciu β-buniek pankreasu
  - podporuje vznik regulačných T-lymfocytov

👉 Cieľ: spomaliť alebo oddialiť nástup klinického diabetu
oddialenie manifestácie DM1T (~2–3 roky)
zachovanie C-peptidu

**Štádium:** najmä **predklinické (stage 2)**

**Status:** ✔ schválený (FDA, aj EU 2026)

👉 zatiaľ jediná terapia s reálnym *preventívnym efektom*

## Teplizumab a diabetes mellitus

### 🧪 Indikácia

Používa sa u:

- osôb s **vysokým rizikom vzniku DM1T** (pozitivita autoprotilátok + porucha glukózovej tolerancie)
- tzv. **predklinické štádium diabetu (stage 2)**

👉 Schválený napr. v USA (FDA) na **oddialenie manifestácie DM1T**

### ⏳ Efekt

Klinické štúdie ukázali:

- oddialenie vzniku DM1T v priemere o ~2–3 roky
- u niektorých pacientov aj dlhšie

# Teplizumab a diabetes mellitus

| Terapia | Cieľ | Efekt na priebeh | Trvanie účinku | Klinický význam |
|---|---|---|---|---|
| **Teplizumab** | T-lymfocyty (CD3) | ★★★★ oddialenie DM | roky | ✔ najväčší |
| Abatacept | T-cell aktivácia | ★★ | dočasný | doplnkový |
| Rituximab | B-lymfocyty | ★★ | krátkodobý | kombinácie |
| AntiThymocyteGlobulin | T-lymfocyty (deplecia) | ★★★★ | stredný | účinný, ale toxickejší |
| Cytokíny | zápal | ★ | slabý | experiment |
| GAD vakcíny | antigén | ★ | neistý | výskum |